Kwangdong Pharmaceutical Reports Stable Q1 2026 Results and Boosts Shareholder Value via Share Buyback Cancellation

Consolidated Q1 2026 sales: KRW 410.8 billion; operating profit: KRW 7.5 billion; net income: KRW 4.9 billion (slight decline vs. proportional prior year)
Completed cancellation of 2,621,043 treasury shares (approx. 5% of total issued) on Jan 9, 2026 → EPS boost
Dividend policy: ≥15% of separate net income for shareholder returns; minimum KRW 100 DPS if net income > KRW 20 billion
License-in agreements: OCU-400 (retinitis pigmentosa), Cetraxal Plus (otitis externa) and other rare disease drugs
Strengthened diagnostics business via additional stake in Precision Bio (from 54.73% to 50.23% post-merger)
Contingent liability: pending lawsuit from South Korea (damage claim of KRW 1.146 billion)
Financial health: debt ratio 85.1%, current ratio 130.0%, cash & equivalents KRW 96.6 billion